Ara
Toplam kayıt 86, listelenen: 71-80
Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: A real-life evidence from biostar nationwide registry
(BMJ Publishing Group, 2023)
Background: Patients with rheumatoid arthritis (RA) have increased morbidity and mortality due to cardiovascular (CV) comorbidities. Objectives: The association of CV diseases (CVD) and traditional CV risk factors have ...
A research on determining the degree of risk by using ResNet
(ISRES Publishing, 2023)
Risk analysis, considered one of the most crucial building blocks of occupational safety with a multidisciplinary approach, is an area that requires quick solutions with proactive methods, has high operational costs, and ...
Diffusion-based hierarchical multi-label object detection to analyze panoramic dental X-rays
(Springer Science and Business Media Deutschland GmbH, 2023)
Due to the necessity for precise treatment planning, the use of panoramic X-rays to identify different dental diseases has tremendously increased. Although numerous ML models have been developed for the interpretation of ...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)
Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ...
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)
Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ...
Turkish translation and crosscultural validity of WHOQoL-HIV Bref Tool
(Wiley, 2023)
...